U.S. Vaccine Panel Delays Vote on J&J Covid-19 Shot's Clot Risk 

The federal government's recommendation to pause using Johnson & Johnson's Covid-19 vaccine will remain in place after an advisory panel put off a vote on how to move forward following reports of a few cases of life-threatening blood clots.

Dell Plans Spinoff of $52 Billion Stake in VMware 

The personal-computer maker said it intends to use net proceeds from the deal to pay down debt.

Dell CFO Looks to Use VMware Proceeds to Bring Down Debt 

"This accelerates our plan to delever the company," Chief Financial Officer Tom Sweet said.

Thermo Fisher Nears Deal to Buy PPD for More Than $15 Billion 

If completed, deal would be the latest tie-up among companies that run clinical trials and provide other services for drugmakers.

Novavax to Participate in Oxford Study Comparing Covid-19 Vaccine Combinations 

A Novavax Covid-19 vaccine will be studied in a Phase 2 trial conducted by the University of Oxford "to evaluate the potential for combined regimens that mix vaccines from different manufacturers to achieve immune protection against Covid-19."

Coinbase Fetches $85 Billion in Value in Trading Debut 

The cryptocurrency exchange is the first major bitcoin-focused company to test the U.S. public market, marking a watershed moment for an industry that began a decade ago as an experiment in digital money.

American-JetBlue Alliance Draws Increased Scrutiny From DOJ 

The Justice Department has stepped up an antitrust probe of American Airlines's recent partnership with JetBlue Airways, concerned the deal could lead to anticompetitive coordination and inflated fares at certain hubs.

Qantas Ramping Up Domestic Capacity Amid Leisure Surge 

Australia's No. 1 airline, Qantas Airways Ltd., said it is increasing domestic capacity faster than expected in response to a surge in demand from leisure travelers as coronavirus restrictions ease.

EU Orders Extra Pfizer Vaccines Amid J&J Suspension 

The European Union, grappling with the potential loss of Johnson & Johnson Covid-19 vaccines, will buy an additional 50 million doses from BioNTech and Pfizer for the quarter, and is in talks to purchase up to 1.8 billion more doses over the next two years.

Bed Bath & Beyond's Improvement Project Is Far From Finished 

The selloff in Bed Bath & Beyond looks overdone considering its unsurprising results, but the retailer still has a way to go to win back confidence.


(END) Dow Jones Newswires

April 15, 2021 01:00 ET (05:00 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.